ライフサイエンスコーパス: malignant mesothelioma

1 athways and eventual sporadic development of malignant mesothelioma.

2 n highly differentiated breast carcinoma and malignant mesothelioma.

3 stos is a major factor in the development of malignant mesothelioma.

4 d mesothelial cells, the progenitor cells of malignant mesothelioma.

5 n malignancies of nonneuronal origin such as malignant mesothelioma.

6 iation therapy and subsequent development of malignant mesothelioma.

7 predispose to several cancers, in particular malignant mesothelioma.

8 shown promising results for the treatment of malignant mesothelioma.

9 ibitor, SM16, in the AB12 syngeneic model of malignant mesothelioma.

10 placebo in patients with previously treated malignant mesothelioma.

11 in patients with previously treated advanced malignant mesothelioma.

12 phase III clinical trials as a treatment for malignant mesothelioma.

13 as a result of Dishevelled overexpression in malignant mesothelioma.

14 cal trials for the treatment of unresectable malignant mesothelioma.

15 ng pathways may be a strategy for therapy of malignant mesothelioma.

16 beta gene (Ad.muIFN-beta) in mouse models of malignant mesothelioma.

17 trated frequent deletions from 15q11.1-15 in malignant mesothelioma.

18 (+/-) knockout mice with asbestos to induce malignant mesotheliomas.

19 ism in the etiology of the majority of human malignant mesotheliomas.

20 ven of 15 patients had histologically proven malignant mesotheliomas (10 epithelial, 1 sarcomatoid).

21 Human malignant mesotheliomas accumulate multiple somatic gene

22 multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line set

23 lly blocking HMGB1, may decrease the risk of malignant mesothelioma among asbestos-exposed cohorts.

24 ates many of the molecular features of human malignant mesothelioma and has significant implications

25 tand the significance of NF2 inactivation in malignant mesothelioma and identify tumor suppressor gen

26 lasms of non-neuroectodermal origin, such as malignant mesothelioma and melanoma.

27 or pathways critical for the pathogenesis of malignant mesothelioma and other NF2-related malignancie

28 y expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung

29 r significant potential for the treatment of malignant mesothelioma and possibly other cancers.

30 tion of asbestos-exposed individuals develop malignant mesothelioma, and because mesothelioma cluster

31 clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphas

32 ovide greater efficacy than monotherapies in malignant mesothelioma are ongoing.

33 New therapeutic strategies for malignant mesothelioma are urgently needed.

34 Malignant mesotheliomas are highly aggressive tumors usu

35 The clinicopathologic characteristics of malignant mesotheliomas arising in these patients have n

36 rwent treatment for pathologically confirmed malignant mesothelioma at Brigham and Women's Hospital a

37 aluated telomerase activity in seven primary malignant mesothelioma biopsies and matched lung specime

38 with asbestos in the development of diffuse malignant mesothelioma, but its precise role in the path

39 Malignant mesothelioma causes profound morbidity and nea

40 Analysis of a panel of malignant mesothelioma cell lines reveals a strong corre

41 uctase inhibitor, induced apoptosis in human malignant mesothelioma cell lines.

42 luate if talc directly effects cell death of malignant mesothelioma cells (MMC) or normal pleural mes

43 Taken together, our findings indicate that malignant mesothelioma cells rely on HMGB1, and they off

44 Malignant mesothelioma cells strongly expressed HMGB1 an

45 Human malignant mesothelioma cells supported the growth of HSV

46 at HMGB1 establishes an autocrine circuit in malignant mesothelioma cells that influences their proli

47 horage-independent growth of HMGB1-secreting malignant mesothelioma cells was inhibited in vitro by t

48 Ovarian cancer and malignant mesothelioma frequently express both mesotheli

49 otheliomas from Nf2 (+/-) mice and in 50% of malignant mesotheliomas from asbestos-exposed WT mice.

50 n, was observed in all nine asbestos-induced malignant mesotheliomas from Nf2 (+/-) mice and in 50% o

51 As in the human disease counterpart, malignant mesotheliomas from the Nf2 (+/-) mice also sho

52 Samples of malignant mesotheliomas, gliomas, sarcomas, and lymphore

53 Malignant mesothelioma has been linked to asbestos expos

54 treatment of non-small cell lung cancer and malignant mesothelioma, has adverse effects including ne

55 ibers may significantly increase the risk of malignant mesothelioma in genetically predisposed indivi

56 Notably, we also observed malignant mesotheliomas in two Bap1-mutant mice, but not

57 tumors unrelated to the NF2 syndrome such as malignant mesothelioma, indicating a broader role for th

58 Malignant mesothelioma is a cancer with poor prognosis a

59 Human malignant mesothelioma is an aggressive and highly letha

60 Malignant mesothelioma is an aggressive and lethal pleur

61 Malignant mesothelioma is an aggressive cancer largely a

62 Malignant mesothelioma is an aggressive neoplastic proli

63 Malignant mesothelioma is one of the very few extrarenal

64 s used worldwide, but its capacity to induce malignant mesothelioma is still debated.

65 Malignant mesothelioma is strongly associated with asbes

66 benign and malignant tumor types, including malignant mesothelioma, melanoma, and kidney carcinoma.

67 the causal relationship established between malignant mesothelioma (MM) and asbestos exposure, the e

68 Malignant mesothelioma (MM) arising in the peritoneal ca

69 ays, to fine map genomic imbalances in human malignant mesothelioma (MM) cell lines derived from prim

70 identify chromosomal imbalances in 24 human malignant mesothelioma (MM) cell lines derived from untr

71 e expression changes in rat asbestos-induced malignant mesothelioma (MM) cells were investigated by d

72 nt study, we determined IL-8 levels in human malignant mesothelioma (MM) effusions and congestive hea

73 Malignant mesothelioma (MM) is a cancer of the lining of

74 Malignant mesothelioma (MM) is a relatively rare but dev

75 Malignant mesothelioma (MM) is an aggressive malignancy,

76 Malignant mesothelioma (MM) is an aggressive tumor with

77 Malignant mesothelioma (MM) is associated with asbestos

78 -like mineral, causes unprecedented rates of malignant mesothelioma (MM) mortality in some Turkish vi

79 Malignant mesothelioma (MM) of pleura is an aggressive a

80 the effect of the micronutrient selenium on malignant mesothelioma (MM) progression, we cultured fou

81 ls of naturally occurring asbestos (NOA) and malignant mesothelioma (MM) risk.

82 th unresectable and histologically confirmed malignant mesothelioma (MM) were eligible.

83 Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase I

84 ng to the development and chemoresistance of malignant mesothelioma (MM), an aggressive asbestos-asso

85 Malignant mesothelioma (MM), is an intractable disease w

86 tion of subjects exposed to asbestos develop malignant mesothelioma (MM), suggesting that additional

87 susceptible to accelerated asbestos-induced malignant mesothelioma (MM).

88 a tumor suppressor frequently inactivated in malignant mesothelioma (MM).

89 Asbestos is the main cause of human malignant mesothelioma (MM).

90 We compared the methylation profile of 66 malignant mesotheliomas (MMs) and 40 lung adenocarcinoma

91 Malignant mesotheliomas (MMs) are aggressive tumors deri

92 Malignant mesotheliomas (MMs) are very aggressive tumors

93 Our previous cytogenetic studies of malignant mesotheliomas (MMs) revealed losses from 6q15-

94 ications for the further characterization of malignant mesothelioma pathogenesis and preclinical test

95 that cooperate with NF2 loss of function in malignant mesothelioma pathogenesis, we treated Nf2 (+/-

96 Accordingly, HMGB1 levels in malignant mesothelioma patient sera were higher than tha

97 orted an association between pleural diffuse malignant mesothelioma (PDMM) and chest radiation for ly

98 The inability to forecast outcomes for malignant mesothelioma prevents clinicians from providin

99 d for other diseases, including lung cancer, malignant mesothelioma, pulmonary inflammation, surfacta

100 Malignant mesothelioma remains an incurable disease for

101 analyses were also done on a series of human malignant mesothelioma samples.

102 opriate treatment for selected patients with malignant mesothelioma selected using a revised staging

103 equent losses of chromosome 1p21-22 in human malignant mesothelioma, suggesting that the loss or inac

104 Except for malignant mesotheliomas, the role of NF2 mutation or ina

105 developed a multicellular spheroid model of malignant mesothelioma to investigate molecular mechanis

106 suggesting a novel therapeutic approach for malignant mesothelioma treatment.

107 f2 (+/-) mice exhibited markedly accelerated malignant mesothelioma tumor formation compared with asb

108 ows potent activity against established AB12 malignant mesothelioma tumors using an immune-mediated m

109 mor recurrence after resection of bulky AB12 malignant mesothelioma tumors.

110 Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice show

111 ensity loss of heterozygosity analysis of 46 malignant mesotheliomas, using 26 polymorphic microsatel

112 (-/-) malignancies in their lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

113 Four cases of malignant mesothelioma were observed following Hodgkin's

114 imary tumor specimens and cell lines from 50 malignant mesotheliomas were examined for loss of hetero

115 and is present in the serum of patients with malignant mesothelioma, which could negatively affect th

116 ents with unresectable pleural or peritoneal malignant mesothelioma who had progressed after one or t

117 GB1 inhibition in vivo reduced the growth of malignant mesothelioma xenografts in severe-combined imm

118 strongly associated with the development of malignant mesothelioma, yet the mechanistic basis of thi